{
 "name": "國邑",
 "slug": "tw-6875",
 "aliases": [
  "國邑藥品科技股份有限公司",
  "PBI",
  "6875"
 ],
 "ticker": "6875",
 "industry": "生技醫療業",
 "website": "https://www.pharmosa.com.tw",
 "summary": "國邑（6875）是上櫃的生技醫療類股公司，2000 年成立，2024 年上櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "國邑藥品科技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "英文簡稱",
   "value": "PBI",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心上櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "上櫃日期",
   "value": "2024-03-26",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "成立日期",
   "value": "2000-05-25",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "董事長",
   "value": "王建治",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "總經理",
   "value": "甘霈",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "實收資本額",
   "value": 645914020,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "公司網址",
   "value": "https://www.pharmosa.com.tw",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 4550,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原基本資料數值、單位、as_of保留；2026-10-22逐欄核對官方月營收API，與原值（百分比四捨五入至二位）一致。官方出表日期：2026-10-17。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": -66.49,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原基本資料數值、單位、as_of保留；2026-10-22逐欄核對官方月營收API，與原值（百分比四捨五入至二位）一致。官方出表日期：2026-10-17。"
  },
  {
   "claim": "管線：L606（liposomal treprostinil）",
   "value": "間質性肺病相關肺高壓｜Re-Spire第三期招募中｜美國、加拿大、歐洲及澳洲",
   "unit": "",
   "as_of": "2026-10-14",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07285655",
   "note": "NCT07285655；登錄狀態與日期依最後更新版本；地區依登錄試驗中心，不將全球試驗名稱外推至未登錄國家。"
  },
  {
   "claim": "管線：L606（liposomal treprostinil）",
   "value": "肺動脈高壓及肺病相關肺高壓｜第三期安全性試驗進行中、不再招募｜美國",
   "unit": "",
   "as_of": "2026-04-01",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT04691154",
   "note": "NCT04691154；登錄狀態與日期依最後更新版本；"
  },
  {
   "claim": "管線：L608（iloprost）",
   "value": "系統性硬化症相關指端潰瘍｜美國FDA第二期IND核准｜美國",
   "unit": "",
   "as_of": "2026-09-18",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "發言日期：2026-09-18；主旨：本公司吸入新藥L608(微脂體-伊洛前列素)，通過美國食品藥物管理局(FDA)人體二期臨床試驗審查(IND)。IND核准不等於已首例給藥或取得上市藥證。"
  },
  {
   "claim": "管線：L608（iloprost；健康成人PK試驗）",
   "value": "健康成人安全性、耐受性及藥物動力學｜第一期招募中｜紐西蘭",
   "unit": "",
   "as_of": "2026-07-22",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06429930",
   "note": "NCT06429930；登錄狀態與日期依最後更新版本；與美國SSc-DU二期為不同試驗；健康成人不當治療適應症。"
  },
  {
   "claim": "催化劑：L608",
   "value": "紐西蘭一期試驗預估完成｜2026-12-31（試驗登錄預估）｜已公告",
   "unit": "",
   "as_of": "2026-07-22",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06429930",
   "note": "NCT06429930；登錄狀態與日期依最後更新版本；completionDateStruct.type=ESTIMATED，非保證結果公布日。"
  },
  {
   "claim": "簽約金：L606（Liquidia；2023北美授權）",
   "value": 10000000,
   "unit": "美元",
   "as_of": "2023-06-28",
   "source": "https://www.pharmosa.com.tw/news/f30783",
   "note": "付款義務，公告未表示已收；不列入已收金額。"
  },
  {
   "claim": "里程碑金上限：L606（Liquidia；2023北美授權）",
   "value": 215000000,
   "unit": "美元",
   "as_of": "2023-06-28",
   "source": "https://www.pharmosa.com.tw/news/f30783",
   "note": "開發及銷售里程碑合計上限，附條件；另每新增適應症/產品核准1000萬美元不併入既有上限。"
  },
  {
   "claim": "簽約金：L606（Liquidia；2024擴區增訂）",
   "value": 3500000,
   "unit": "美元",
   "as_of": "2024-10-02",
   "source": "https://www.pharmosa.com.tw/news/2d49ff",
   "note": "僅2024擴區增訂部分，非累計已收。"
  },
  {
   "claim": "里程碑金上限：L606（Liquidia；2024擴區增訂）",
   "value": 157750000,
   "unit": "美元",
   "as_of": "2024-10-02",
   "source": "https://www.pharmosa.com.tw/news/2d49ff",
   "note": "新增開發及北美以外商業銷售里程碑；附條件，非已收。"
  },
  {
   "claim": "權利金比率：L606（Liquidia）",
   "value": "低雙位數、兩級距",
   "unit": "%",
   "as_of": "2024-10-02",
   "source": "https://www.pharmosa.com.tw/news/2d49ff",
   "note": "全球L606淨銷售額之兩級距低雙位數權利金；未公開精確百分比，不換算。"
  },
  {
   "claim": "授權合作：L606（2023北美授權公告）",
   "value": "Liquidia Technologies, Inc.｜北美｜2023-06-28",
   "unit": "",
   "as_of": "2023-06-28",
   "source": "https://www.pharmosa.com.tw/news/f30783",
   "note": "付款義務，公告未表示已收；不列入已收金額。 末段為公告日；同源說明已訂立專屬開發及商業化授權，但精確簽署日查無。2023年原約簽約金1,000萬美元與里程碑上限2.15億美元是合約條件，未稱已收；不與2024擴區條款混作同筆新增收款。"
  },
  {
   "claim": "授權合作：L606（2024擴區增訂公告）",
   "value": "Liquidia（同源公告之合約方）｜北美外增列歐洲、日本等市場（保留地區詳note）｜2024-10-02",
   "unit": "",
   "as_of": "2024-10-02",
   "source": "https://www.pharmosa.com.tw/news/2d49ff",
   "note": "僅2024擴區增訂部分，非累計已收。 末段為增訂公告日，精確簽署日查無。增訂現有專屬授權，增加北美以外地域及霧化器權利；國邑保留中國、韓國、台灣、中東、北非、土耳其及東南亞。增訂簽約金350萬美元與額外里程碑上限1.5775億美元，不是原約累計已收；低雙位數兩級距權利金條款未變。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6875.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}